Dishman Carbogen Amcis Quarterly Results for Trading Insights
In Mar 2026, Dishman Carbogen Amcis (DCAL) reported revenue ₹868 Cr and net profit ₹22 Cr — revenue +19.9% YoY. View DCAL yearly price range for the annual high/low range and current price position.
DCAL Quarterly Results — Revenue, Profit & EPS Highlights
Dishman Carbogen Amcis latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit DCAL share price screener.
- Revenue of ₹868 Cr in Mar 2026 (+24.7% vs Jun 2026, +19.9% vs Mar 2025)
- Net Profit of ₹22 Cr in Mar 2026 (+137.9% vs Jun 2026, -48.8% vs Mar 2025)
- EBITDA of ₹178 Cr in Mar 2026 (+131.2% vs Jun 2026)
- Operating Margin of 19.0% in Mar 2026 (+10.0pp vs Jun 2026)
- Earnings Per Share of ₹1.39 in Mar 2026 (+137.7% vs Jun 2026)
Dishman Carbogen Amcis Quarterly Results — Revenue, EBITDA, Net Profit & EPS
DCAL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 868 | 696 | 661 | 724 | 733 | 24.7% | 19.9% |
| Net Profit (₹ Cr) | 22 | -58 | 65 | 43 | 23 | - | - |
| EBITDA (₹ Cr) | 178 | 77 | 157 | 149 | 163 | - | - |
| EPS (₹) | 1.39 | -3.69 | 4.16 | 2.75 | 1.49 | - | - |
| Operating Margin (%) | 19.0% | 9.0% | 23.0% | 20.0% | 19.0% | - | - |
DCAL Share Price Trend — 1-Year Movement Across Quarterly Results
Dishman Carbogen Amcis 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse DCAL institutional holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
DCAL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Dishman Carbogen Amcis latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores